91 results about "Target binding" patented technology

Embodiments of the present disclosure relate to modeling DEL data using factorized molecular representations (e.g., hierarchical single and double synthon building blocks), which leverages the hierarchical structure inherent to these molecules. Using factorized molecular representations, machine learning models are trained to learn the underlying binding affinity of compounds to targets and one or more covariates (e.g., loading / repeat noise). This results in machine learning models producing improved predictions in the form of higher enrichment scores that have good correlation with compound-target binding affinity.

The invention discloses a 5-bromoindole-2-carboxylic acid methyl ester derivative as well as a preparation method and application thereof in a protein inhibitor, and relates to the technical field of synthesis and preparation of inhibitors. According to the 5-bromoindole-2-carboxylic acid methyl ester derivative, compared with a contrast product, the synthetic route steps of the prepared 5-bromoindole-2-carboxylic acid methyl ester derivative are simpler and more convenient, structural modification and preparation are easier, the application range of a substrate is widened, the yield of the product is increased, and the yield of the product is increased. The differentiated requirements on the molecular structure novelty in the field of kinase inhibitors can be met. An epidermal growth factor receptor (EGFR) inhibitor prepared from the 5-bromoindole-2-carboxylic acid methyl ester derivative is higher in inhibition efficiency on biological activity, the physiological solubility is improved more remarkably, a more excellent and stable target binding result can be shown, and the EGFR inhibitor can be used for preparing an epidermal growth factor receptor (EGFR) inhibitor. The application effect of the compound in scenes such as antitumor drug development and the like is favorably improved.

This invention discloses a KK-LC-1 targeting binding protein and its derivatives, a kit, and applications. The protein sequence of the KK-LC-1 targeting binding protein is shown in one of SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, and SEQ ID No. 5. The KK-LC-1 targeting binding protein of this invention has a molecular weight of only about 17 kDa, approximately one-tenth that of an antibody, exhibiting good tissue penetration. Furthermore, its production process is simple and yields high quantities. The targeting binding protein of this invention demonstrates good targeting activity against KK-LC-1-positive tumors both in vivo and in vitro, and can be used for targeted tumor drug delivery, representing a potential drug for tumor immunotherapy. Simultaneously, a KK-LC-1 serum detection kit was developed using the targeting binding protein, enabling quantitative detection of KK-LC-1 levels in the human body.

The application discloses use of LncRNA00_178, miR-466b-3p and Gucy1b1 as acute lung injury markers or drug targets, and belongs to the technical field of biomarkers and drug targets. LncRNA00_178 can be used as a biomarker for screening or diagnosing acute lung injury, a miR-466b-3p down-regulator can be used to prepare a pharmaceutical composition for preventing and treating acute lung injury, and Gucy1b1 can be used as a drug target to prepare a drug for preventing and / or treating acute lung injury. The application has the beneficial effects that the application proposes that LncRNA00_178 and miR-466b-3p, and miR-466b-3p and Gucy1b1 have a target binding relationship. LncRNA00_178 can be used as a biomarker for screening or diagnosing acute lung injury, the silence of miR-466b-3p inhibits LPS-induced apoptosis of alveolar epithelial cells, and Gucy1b1 can be used as a drug target to prepare a drug for preventing and / or treating acute lung injury. The data provide new insights for the treatment mechanism of ALI and the identification of specific targets, and provide a new idea for the research and development of new drugs for acute lung injury, and have a wide application prospect.

The present disclosure addresses the problem of providing technology for phagocytizing unwanted cells or the like in vivo.　This protein includes, from the N-terminus to the C-terminus, (A) a target binding region that binds to a target, and (C) an SHBG-like domain of ProS.

Disclosed herein are methods and compositions for detecting (+)-methamphetamine using dye-complexed and redox-tag-labeled aptamers that generate a detectable signal upon target binding.

The invention discloses application of a cacumen biotae extract in activating Nrf2 protein in cells, and particularly relates to the field of cosmetics. Wherein the activation of the Nrf2 protein in the cell is realized by interrupting the Keap1-Nrf2 protein-protein interaction in the cell, and performing targeted combination with the Keap1 protein and releasing the Nrf2 protein. By activating the Nrf2 pathway, the Chinese arborvitae twig and leaf extract can simultaneously achieve anti-oxidation, anti-inflammatory, anti-aging and whitening effects, and meets the requirements of cosmetics for multi-target effects.

This application discloses a method, apparatus, and computer device for evaluating ligand binding sites in a complex. The method involves binding a target ligand to multiple candidate binding sites within a target protein, obtaining a candidate complex conformation corresponding to each candidate binding site; acquiring distance information between each atom of the target protein and each atom of the target ligand in each candidate complex conformation; determining the binding strength information between the target protein and the target ligand in each candidate complex conformation based on the distance information; and determining the target binding site based on the binding strength information. This method can improve the accuracy of ligand binding site evaluation in complexes.

A peptide or a derivative thereof or a salt thereof, including a hydrophobic region, and a hydrophilic region positioned on at least one end side of the hydrophobic region and having hydrophobicity lower than that of the hydrophobic region, including, at one end, a first target binding site capable of binding to a first target, and including, at the other end, a second target binding site capable of binding to a second target. The peptide is applicable to an active targeting DDS.

Embodiments of the disclosure involve modeling DEL data using factorized molecular representations (e.g., hierarchical mono-synthon and di-synthon building blocks), which capitalizes on the inherent hierarchical structure of these molecules. Using the factorized molecular representations, machine learning models are trained to learn latent binding affinity of compounds for targets and one or more covariates (e.g., load / replicate noise). This leads to improved predictions by the machine learning models in the form of higher enrichment scores, which are well-correlated with compound-target binding affinity.

The present application provides a guide RNA for inhibiting off-target binding in CRISPR / Cas9-based genome editing, wherein the guide RNA comprises at least one abasic spacer in a crRNA sequence. The effects of the present invention include inhibiting unintended off-target binding while maintaining the target genome editing effect by CRISPR / Cas9 by weakening the binding force with the target DNA while maintaining the structure of the guide RNA.

A method and device are provided for detecting a target in a biological sample. The target binds to a solid phase substrate. First and second cavities in a plate are filled with an oil. The first and second cavities are in fluid communication with each other. The solid phase substrate is magnetically drawn sequentially from a drop of the biological sample in the first cavity, through the oil, into a drop of the reaction solution in the second cavity. A change in a parameter of the drop of the reaction solution indicates the presence of the target.

This invention proposes a nucleic acid aptamer that specifically binds to human senescent dermal fibroblasts (HDFs), along with its screening, identification, and application. Specific aptamers exhibiting high targeting specificity to human senescent HDFs were screened using Cell-SELEX technology. The three selected candidate aptamers showed binding rates of 57.5%, 86.2%, and 50.7% to senescent HDF cells within the same timeframe, respectively, demonstrating high specificity and targeted binding ability. Furthermore, the aptamer possesses potential for detecting, imaging, and regulating the function of senescent cells, successfully providing a new direction for targeted anti-aging interventions and therapeutic applications.

The application discloses a polypeptide with binding affinity to IL-6 and application thereof. The amino acid sequence of the polypeptide comprises one or more of sequences shown in SEQ ID NO. 1-6. The application obtains the polypeptide with affinity to IL-6 through screening, which can specifically bind to IL-6, so that IL-6 is enriched, and then IL-6 is adsorbed at an inflammation infection site, thereby providing more choices for treatment of diseases related to removal of inflammatory factors and IL-6 overabundance, and the polypeptide can be used for IL-6 detection and preparation of drugs for targeted binding to IL-6 or treatment of diseases related to IL-6.

The purpose of the present invention is to provide lipid nanoparticles capable of efficiently introducing a nucleic acid into T cells. Provided are lipid nanoparticles each comprising: a nucleic acid encapsulated in each of the lipid nanoparticles; a cationic lipid; sterol or a sterol derivative; DSPC; a targeted polyalkylene glycol-modified lipid linked to a target binding site; and a non-targeted polyalkylene glycol-modified lipid to which the target binding site is not linked. The target binding site targets a target site on each T cell. The amount of the cationic lipid is 35.0-55.0 mol% with respect to the total lipid amount of the lipid nanoparticles. The amount of sterol is 25.0-40.0 mol% with respect to the total lipid amount of the lipid nanoparticles. The amount of DSPC is 15.0-35.0 mol% with respect to the total lipid amount of the lipid nanoparticles. The N / P ratio is 8.0-12.0.

The invention discloses a compound targeting AT1R, which is composed of a target head molecule targeting AT1R, a PEG linker, an aspartic acid linker and a chelating agent, and can be used as a component of a PET tracer agent targeting AT1R. A target head molecule can be embedded into a hydrophobic'pocket 'of AT1R protein, so that high-affinity and high-selectivity targeted binding is realized; the PEG connexon can prolong the residence time of the PET tracer agent targeting the AT1R at the tumor part; different numbers of aspartic acids can regulate and control the pharmacokinetic properties of the PET tracer agent targeting the AT1R, reduce the liver and gall and intestinal signal backgrounds of the PET tracer agent targeting the AT1R, and improve the target-to-cost ratio. Therefore, accurate diagnosis and treatment of digestive system diseases such as digestive tract tumor and liver cancer can be realized. The invention further discloses a PET tracer agent targeting AT1R as well as a preparation method and application of the PET tracer agent.

The invention discloses an electrochemical sensor for glycoprotein detection and a glycoprotein detection method. The method comprises the following steps: anchoring an aptamer-protein conjugate on the surface of a gold electrode, and then assembling an anti-fouling peptide around the aptamer-protein conjugate to form an imprinted self-assembled monolayer film. And removing the combined protein through an acid solution to form a biocompatible imprinting cavity capable of being used for recombining a target object. The imprinted cavity can eliminate non-specific adsorption and enhance targeted binding efficiency. The sensor can be used for directly detecting carcino-embryonic antigens with the concentration as low as 0.1 ng / mL through an electrochemical impedance spectroscopy method. Besides, homodimer concanavalin A (ConA) is used as a recognition element and a cross-linking agent, homodimer glucose oxidase (GOx) is assembled on the surface of the electrode in situ, a protein network can be formed, and enzyme catalysis signal amplification detection is achieved. Through in-situ formation of a ConA-GOx assembly, the sensitivity is improved by 100 times.

Described herein are reagents and methods for improving signal in imaging mass cytometry. Aspects include mass tags with a large number of labeling atoms, chemical modifications to mass tags and additional reagents to reduce background and / or maintain target binding of mass tagged specific binding partners (SBPs), and schemes for associating a plurality of mass tags with a single SBP. As such, embodiments include any combination of one or more reagents and their use. The reagents, kits and methods herein may be used for mass cytometry, including imaging mass cytometry. In some aspects, reagents, kits or methods may be used for delivery of a large number of radioisotopes to a target analyte, for example for therapeutic use or radiometric detection. In certain aspects, only non-radioactive isotopes may be used for mass cytometry.

The application discloses a drug-target binding affinity prediction model training method and a prediction method based on contrast learning, and belongs to the technical field of drug-target binding affinity prediction. In order to solve the problem that the prediction effect of the existing DTA prediction based on contrast learning needs to be improved, the application selects positive and negative samples according to the similarity between drug molecular structures, the similarity between target sequences, and the similarity between drugs and targets in an affinity graph to optimize the effect of contrast learning, extracts drug-target features of three different scales of sequences, molecular structures and affinity graphs, fully utilizes drug and target information, captures potential relationships between cross-scale feature information through a multi-scale feature contrast learning framework, maximizes mutual information between different scales, and performs feature alignment and feature fusion, and then obtains a prediction model based on contrast loss, and the prediction model is used to realize drug-target binding affinity prediction.

The present application relates to the application of active ingredients in Lonicera japonica in antioxidant stress, the active ingredients in Lonicera japonica break the Keap1-Nrf2 protein-protein interaction in cells, activate Nrf2 pathway, and target binding Keap1 protein, release Nrf2 protein, and activate the mode of antioxidant enzyme to play the role of antioxidant.The present application first proves by experiment that the active ingredients in Lonicera japonica target binding Keap1 protein and break Keap1-Nrf2 PPI, release Nrf2 protein, and activate the expression of downstream antioxidant enzymes (such as NQO1), so as to realize the effect of antioxidant.

The purpose of the present invention is to provide lipid nanoparticles capable of efficiently introducing drugs into cells, and constituent lipids of the lipid nanoparticles. Provided are lipid nanoparticles including nucleic acids encapsulated within the lipid nanoparticles, cationic lipids, and targeted polyalkylene glycol-modified lipids linked to a target binding site, wherein the target binding site targets a target site on a target cell.

Provided are anti-idiotype antibodies that specifically recognize anti-GPRC5D antibody moieties, in particular, anti-GPRC5D antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of antiidiotype antibodies for specifically identifying and / or selecting cells expressing such recombinant receptors, such as anti-GPRC5D CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.

The present invention refers to an oligonucleotide consisting of a core sequence of ATATTTAGGTCCAGCG (SEQ ID NO:1) or AATATTTAGGTCCAGCG (SEQ ID NO:2) and at least one additional nucleotide at the 3´-end and optionally at least one additional nucleotide at the 5´-end. At least one of the nucleotides of the oligonucleotide is modified, and the oligonucleotide binds to pre-mRNA of neuropilin 1 (NRP1, CD304). The invention is further directed to a pharmaceutical composition comprising such oligonucleotide. The pharmaceutical composition and the oligonucleotide are for use in a method of preventing and / or treating cancer, an ophthalmic disease, an autoimmune disorder and / or an immune disorder.

A proteolysis targeting chimera is provided of Formula I:wherein: T includes a target binding moiety capable of binding to a target protein; L includes a linker moiety; and U includes a ubiquitin ligase-recruiting moiety capable of binding a ubiquitin ligase; wherein any of T, L, or U further includes a first stimulus-reactive moiety S1, wherein S1 is reactive to a first stimulus; and wherein any of T, L, or U further includes a second stimulus-reactive moiety S2, wherein S2 is reactive to a second stimulus, wherein the second stimulus is different than the first stimulus.

The invention provides an NFT protein, a preparation method and application thereof, and a purification method of NusA or NusA fusion protein, and belongs to the field of recombinant protein expression and purification. The NFT protein provided by the invention has a core function of specifically binding protein purification tag NusA protein, and can be used as a key tool for targeted binding and efficient purification of NusA fusion protein. Compared with a traditional NusA fusion protein purification method which depends on additional addition of 6 * His and other purification labels, the NFT protein can be combined with the NusA protein in a high-affinity and specific manner, the problem of impurity residues of a purified product caused by non-specific combination can be effectively avoided, and the purification purity and recovery rate of the NusA fusion protein are remarkably improved. The NFT protein provided by the invention provides a brand new solution for efficient purification of NusA fusion protein, and has important application value in the fields of research and development of recombinant protein drugs, industrial enzyme production, life science research and the like.

A CDK9-Cyclin T1 protein interaction inhibitor and application thereof are used for preparing a medicine for treating diseases related to CDK9, CDK9 / Cyclin T1 activity or expression amount. By targeting binding of CDK9, the protein interaction of CDK9 and Cyclin T1 is destroyed, and then the related signal path is regulated, tumor cell apoptosis is induced, and the effect of inhibiting tumor cell proliferation is achieved. Therefore, the CDK9-Cyclin T1 protein interaction inhibitor disclosed in the application can be used for treating cancer or related diseases.

The present invention relates to a method of binding a matrix (20) of a cell culture, comprising the steps of: a. Providing (100) a cell culture comprising at least one cell (10) wherein the cell culture comprises a matrix (20); and b. Contacting the cell culture with at least one first component (31) of a biological, chemical and / or physical capture system (30) and incubating (300), wherein the first component (31) of the capture system (30) is a component bound to the substrate (20, 21); and c. Contacting a tool (40) with the cell culture and incubating (500) wherein the tool (40) comprises at least one capture molecule (41), and wherein the capture molecule (41) binds or is bound to a second component (32) of a capture system (30, 31, 32); and d. Obtaining (600) the substrate (20, 21) bound by means of the capture system (30, 31, 32).

The embodiment of the invention provides a data processing method and a task platform. The data processing method comprises the following steps: acquiring a ligand to be screened and a target protein conformation; determining at least one binding channel corresponding to the target protein conformation; calculating channel energy information of each combination channel corresponding to the ligand to be screened, and obtaining channel attribute information corresponding to each combination channel; determining a combination weight corresponding to each combination channel according to the channel energy information and the channel attribute information of each combination channel; and selecting a target binding channel corresponding to the to-be-screened ligand and the target protein conformation according to each binding weight. According to the method, an index for measuring the binding difficulty degree of the protein and the ligand is obtained by utilizing the results of channel analysis and energy analysis through a probability statistics method. And false sun conditions can be effectively screened and filtered.